Dan Harris, international lawyer at Harris Bricken and founding author of the China Law Blog talks about companies leaving China. Are any coming here?
Companies continue to invest in domestic solar thanks to all the new renewable energy tax credits. Without them, and tariffs, US solar would be China owned.
Trump’s call to reshore pharmaceutical production, especially critical medicine in short supply, will set the table for other presidential candidates. Reshoring America’s medicine supply chain is increasingly mainstream, and an easy sell to voters.
Big trouble in China as Washington increasingly warns American businesses to “stay at your own risks”.
Tariffs — and China risks — have helped U.S. reshore and led to more investments in production, shifting the decades old focus away from offshoring.
Alexander Hamilton advocated for trade tariffs and strong IP protections to build the U.S. economy and protect it from more powerful, or more devious adversaries. A debate in DC over whether we are heading towards Hamiltonian economics.
The Covid-19 pandemic gave big pharma big payday. But it also caused the industry to rethink a globalized supply chain centered on Asia. What will it take to reshore at least some generic drugs to the U.S.
Can the U.S. really bring manufacturing home? A McKinsey study shows that existing concentration of some supply chains will make it hard. Here’s what needs to be done.
By Charles Benoit, CPA Trade Counsel In December, the U.S.-China Commission, a group created by Congress to advise on managing the bilateral relationship, formally recommended that China lose its Most-Favored Nation (MFN) tariff status. Referencing the decision to grant China permanent MFN status in 2001, Speaker McCarthy said in remarks on the House floor yesterday…
A Senate Commerce subcommittee hearing heard from witnesses who said worker shortages will ultimately be a drag on U.S. reshoring efforts. Pharmaceutical reps warned of high energy costs, which could add to import dependence.